{
  "dialect": "postgresql",
  "description": "Pricing Schema Catalog",
  "tables": [
    {
      "name": "pricing_calculations_tablets",
      "description": "Pricing Data for brand names",
      "primary_key": [
        "ndc"
      ],
      "columns": [
        {
          "name": "brand_name",
          "type": "varchar",
          "description": "brand name of the drug"
        },
        {
          "name": "disease",
          "type": "varchar",
          "description": "disease related to the drug dosing"
        },
        {
          "name": "wac_unit_effective_date",
          "type": "datetime",
          "description": "date for update of wac unit price which is used to calculate annual cost"
        },
        {
          "name": "total_cost_of_therapy",
          "type": "numeric",
          "description": "total annual cost of the drug for the specific NDC code"
        }
      ]
    },
    {
      "name": "historical_pricing",
      "description": "WAC unit prices for all NDC codes over time",
      "primary_key": [
        "ndc"
        ],
        "columns": [
          {
            "name": "ndc",
            "type": "varchar",
            "description": "NDC Code for the brand name"
          },
          {
            "name": "brand_name",
            "type": "varchar",
            "description": "brand name of the drug"
          },
          {
            "name": "wac_unit_price",
            "type": "numeric",
            "description": "wac unit price reported at wac_unit_effective_date"
          },
          {
            "name": "wac_unit_effective_date",
            "type": "datetime",
            "description": "date for update of wac unit price"
          },
          {
            "name": "strength",
            "type": "varchar",
            "description": "drug strength"
          },
          {
            "name": "dosage_form",
            "type": "varchar",
            "description": "dosage form"
          }
        
        ]
    },
    {
      "name": "drug_classes",
      "description": "ATC Coded drug classes for drugs ",
      "primary_key": [
        "brand_name"
      ],
      "columns": [
        {
          "name": "brand_name",
          "type": "character varying",
          "description": "brand name for a specific drug"
        },
        {
          "name": "atc_class_name",
          "type": "character varying",
          "description": "Possible Values: Cyclin-dependent kinase (CDK) inhibitors,Pyrimidine analogues,Other antineoplastic agents,Combinations of monoclonal antibodies and antibody drug conjugates,Anaplastic lymphoma kinase (ALK) inhibitors,Various therapeutic radiopharmaceuticals,Other immunosuppressants,Aromatase inhibitors,Other immunostimulants,Other hormone antagonists and related agents,Antivirals,VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitors,Antineoplastic cell and gene therapy,BCR-ABL tyrosine kinase inhibitors,EGFR (Epidermal Growth Factor Receptor) inhibitors,Other plant alkaloids and natural products,Mitogen-activated protein kinase (MEK) inhibitors,Poly (ADP-ribose) polymerase (PARP) inhibitors,HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors,Enzymes,Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors,Selective immunosuppressants,Detoxifying agents for antineoplastic treatment,Other antianemic preparations,Alkyl sulfonates,Janus-associated kinase (JAK) inhibitors,Monoclonal antibodies,Interferons,Fourth-generation cephalosporins,Other hematological agents,Other drugs affecting bone structure and mineralization,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors,B-Raf serine-threonine kinase (BRAF) inhibitors,Isocitrate dehydrogenase (IDH) inhibitors,Phosphatidylinositol-3-kinase (Pi3K) inhibitors,Interleukin inhibitors,CD20 (Clusters of Differentiation 20) inhibitors,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,Proteasome inhibitors,Other antithrombotic agents,Histone deacetylase (HDAC) inhibitors,Other monoclonal antibodies and antibody drug conjugates,Combinations of antineoplastic agents,Various alimentary tract and metabolism products,CD38 (Clusters of Differentiation 38) inhibitors,Hedgehog pathway inhibitors,Preparations increasing uric acid excretion,Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors,Anti-androgens,Anti-estrogens,Other protein kinase inhibitors,Colony stimulating factors,Bruton's tyrosine kinase (BTK) inhibitors,CD22 (Clusters of Differentiation 22) inhibitors,Antineovascularisation agents"
        }
      ]
    }
  ]
}